New products and interventions - MRC e-Val 2010
A total of 366 new products and interventions at various stages of development were recorded by MRC e-Val, ranging from diagnostic tools to support tools for fundamental research and drugs. These reports were submitted by 262 unique researchers (approximately 8% of principal investigators) and represent a 20% increase over the information submitted in 2009.
Researchers reported the year in which the product or intervention under development had reached the current stage of development – from initial development to widespread adoption. There were 199 reports of products in initial or refinement stages, 102 reports of products in early or late stage clinical evaluation, and a total of 54 new products and interventions launched onto the market since 2006 (30 since 2009), with a further 11 currently undergoing the process of market authorisation.
The section gives examples of a variety of these new products and interventions, made possible by MRC research investment, from monoclonal antibodies to a new diagnostic test for oesophageal cancer.
